Multiple Myeloma (MM) is the second most common hematological malignancy worldwide and the third most common in China. It originates from plasma cells in the bone marrow, which are "immune warriors" that normally synthesize antibodies to fight infection. When these cells become malignant, they proliferate uncontrollably, crowding out healthy cells and destroying bone and kidney functions. Due to its insidious onset and diverse symptoms, the misdiagnosis rate is as high as 50%

Minimally Invasive Cardiovascular Surgery (MICS) is one of the fastest-developing subspecialties in cardiovascular surgery. Due to less trauma, fewer complications, and faster recovery, MICS is a key development direction. The China National Minimally Invasive Cardiovascular Surgery Professional Committee (CMICS) promotes aligning domestic techniques with international standards. The goal is to summarize MICS progress in China, its clinical effects, and future trends.

Driven by continued Chinese innovation, robust market demand, and industrial upgrades, the DBS industry is poised for a significant development period. It is expected that China will play an increasingly pivotal role in the field of neuro-modulation, offering more "Chinese Solutions" to global neurological disorder patients in the years to come.

China has established a robust clinical research framework for thalassemia gene therapy through collaboration among leading medical centers and biotech companies. With the accumulation of positive clinical data and optimization of protocols, gene therapy is poised to offer a potential functional cure for many thalassemia patients, demonstrating China's growing capability and potential in the global advanced therapy landscape.

Unlike traditional radiotherapy, which employs X-rays or gamma rays, proton beams exhibit a unique energy deposition pattern in matter. They deliver a lower dose as they enter the body and release most of their energy at a specific depth, known as the Bragg Peak. This Bragg Peak effect allows proton therapy to precisely concentrate a higher radiation dose on the tumor while minimizing damage to surrounding healthy tissues, achieving targeted "precision bombing" to cancer cell

The field of diabetes cell and gene therapy exhibits a development landscape where the United States and China possess distinct advantages: 1. The United States maintains leadership in original technology. 2. China holds advantages in the speed of clinical translation and patient resources. 3. International cooperation and complementarity are key for the future.

We are honored to announce that HANGZHOU MEDTOURCHINA TECHNOLOGY CO., LTD has been officially admitted as a BLUE Member of the Health Tourism Development Center of Islamic Countries (HTDC)! 🌍

We’re delighted to announce that MedTourChina has officially signed a Framework Strategic Cooperation Agreement with Healtra, a doctor-led healthcare cooperation. This partnership marks the beginning of a new phase of collaboration between China and the GCC region, focusing on knowledge exchange, medical coordination, and healthcare innovation.

Paitent's Guide: A Practical Hospital Selection Guide for Expatriates in China | China Medical Tourism | MedTourChina | China Hospital | Private Hospital | International Department